Neutrophils escort circulating tumour cells to enable cell cycle progression
A better understanding of the options that outline the interaction between cancer cells and immune cells is vital for the event of latest cancer therapies1. However, focus is usually given to interactions that occur at intervals the first tumor and its microenvironment, whereas the role of immune cells throughout cancer dissemination in patients remains mostly uncharacterized2,3. current tumor cells (CTCs) are precursors of metastasis in many styles of cancer4,5,6, and are sometimes found at intervals the blood in association with non-malignant cells like white blood cells (WBCs)7,8. The identity and performance of those CTC-associated WBCs, also because the molecular options that outline the interaction between WBCs and CTCs, are unknown. Here we tend to isolate and characterize individual CTC-associated WBCs, also as corresponding cancer cells at intervals every CTC–WBC cluster, from patients with carcinoma and from mouse models. we tend to use single-cell RNA sequencing to indicate that within the majority of those cases, CTCs were related to neutrophils. once scrutiny the transcriptome profiles of CTCs related to neutrophils against those of CTCs alone, we tend to notice variety of differentially expressed genes that define cell cycle progression, resulting in a lot of economical metastasis formation. Further, we tend to determine cell–cell junction and cytokine–receptor pairs that outline CTC–neutrophil clusters, representing key vulnerabilities of the pathologic process process. Thus, the association between neutrophils and CTCs drives cell cycle progression at intervals the blood and expands the pathologic process potential of CTCs, providing a explanation for targeting this interaction in treatment of carcinoma. 
Dendritic cells as cancer therapeutics
The ability of immune therapies to manage cancer has recently generated intense interest. This therapeutic outcome is dependent on T lymphocyte recognition of growth cells. The natural perform of nerve fiber cells (DC) is to get adaptive responses, by presenting matter to T cells, therefore they’re a logical target to get specific anti-tumour immunity. Our understanding of the biology of DC is increasing, and that they are currently celebrated to be a family of connected subsets with variable options and performance. Most clinical expertise up to now with DC vaccination has been victimisation monocyte-derived DC vaccines. there’s currently growing expertise with various blood-derived DC derived vaccines, in addition like multiple types of growth matter and its loading, a good vary of adjuvants and totally different modes of immunogen delivery. Key insights from pre-clinical studies, and lessons learned from early clinical testing drive progress towards improved vaccines. The potential to fortify responses with different modalities of therapy makes clinically effective “second generation” DC vaccination methods a priority for cancer immune therapists. 
Circulating tumor cells and their role in prostate cancer
Circulating tumour cells (CTC) became a crucial biomarker in patients with advanced glandular cancer. Counterterrorist Center count has been incontestible to be a prognostic issue for overall survival in patients with pathologic process castration-resistant glandular cancer (mCRPC). In localized glandular cancer, a transparent correlation between Counterterrorist Center counts and clinicopathological risk parameters and outcome has not been discovered. Currently, the main target of analysis is shifting from Counterterrorist Center enumeration towards molecular characterization of CTC resulting in the invention of markers predicting treatment response. The role of steroid hormone receptor splice variants expressed by Counterterrorist Center as markers of resistance to abiraterone and enzalutamide has been assessed by numerous studies. The identification of Counterterrorist Center markers predicting treatment response represents a key step to guide the choice of treatment (e.g., abiraterone/enzalutamide vs taxanes), notably in patients with mCRPC. As another to Counterterrorist Center, the analysis of current tumour deoxyribonucleic acid has been shown to alter a noninvasive unwellness characterization having high potential to market exactitude medical specialty. 
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
Advanced prostate and bladder cancer are 2 outstanding unmet medical desires for urological oncologists. The high prevalence of those tumours, lack of effective biomarkers and restricted effective treatment choices highlight the importance of basic analysis in these diseases. Galectins are a family of β-galactoside-binding proteins that are oft altered (upregulated or downregulated) during a big selection of growths and have roles in numerous stages of tumour development and progression, as well as immune evasion. particularly, altered expression levels of various members of the galectin family are according in prostate and bladder cancers, which, along with the aberrant glycosylation patterns found in growth cells and also the constituent cell varieties of the tumour microenvironment, may result in malignant transformation and growth progression. Understanding the roles of galectin family proteins within the development and progression of prostate and bladder cancer might yield key insights to tell the clinical management of those diseases. 
Modulatory Effect of a Unani Formulation (Jawarish amla sada) on Cyclophosphamide-induced Toxicity in Tumour Bearing Mice
Aims: Our aim was to review the modulatory result of a Unani seasoner formulation Jawarish amla sada against cyclophosphamide-induced toxicity in neoplasm bearing mice.
Study Design: Non irregular management study.
Place and length of Study: The study was conducted at the Department of Medical Elementology and pharmacology, Jamia Hamdard, Indian capital throughout 2008-10.
Methodology: Study was conducted in Swiss anomaly mice divided in 5 teams (n=6). Animals were challenged with Ehrlich’s pathology neoplasm cells (1×106 cells). Cyclophosphamide (50 mg/kg body weight), associate degree alkylating antitumor drug that particularly affects body substance immune functions, was injected intraperitoneally during a single dose. The protecting result of Unani drug Jawarish amla sada (250 mg/kg body weight) was studied in neoplasm bearing animals treated with cyclophosphamide. Immune operate assessment check like plaque forming cell assay (PFC) and organic chemistry parameters such as activities of inhibitor enzymes and reduced glutathione were measured in mice.
Results: Jawarish amla sada considerably modulated the immunological disorder result of cyclophosphamide as compared to the cluster treated with cyclophosphamide. Jawarish amla sada additionally protected activities of inhibitor enzymes like enzyme, antioxidant, glutathione enzyme and glutathione S-transferase and considerably remodeled level of reduced glutathione in liver and urinary organ of neoplasm bearing mice exposed to cyclophosphamide. Similar protecting result of Jawarish amla sada was determined against elevated lipide peroxidation in these tissues.
Conclusion: Jawarish amla sada showed potential to produce protection against noxious effects of cyclophosphamide in neoplasm bearing mice. The mechanism of action of the drug could also be attributed to numerous antioxidants fortified during this seasoner Unani formulation, that is employed within the ancient system of medication in Indian landmass against many liver ailments. 
 Szczerba, B.M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., Scheidmann, M.C., Donato, C., Scherrer, R., Singer, J. and Beisel, C., 2019. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 566(7745), p.553. (Web Link)
 Bryant, C.E., Sutherland, S., Kong, B., Papadimitrious, M.S., Fromm, P.D. and Hart, D.N., 2019, February. Dendritic cells as cancer therapeutics. In Seminars in cell & developmental biology (Vol. 86, pp. 77-88). Academic Press. (Web Link)
 Maas, M., Hegemann, M., Rausch, S., Bedke, J., Stenzl, A. and Todenhöfer, T., 2019. Circulating tumor cells and their role in prostate cancer. Asian journal of andrology, 21(1), p.24. (Web Link)
 Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
Neus Martínez-Bosch, Alejo Rodriguez-Vida, Núria Juanpere, Josep Lloreta, Ana Rovira, Joan Albanell, Joaquim Bellmunt & Pilar Navarro
Nature Reviews Urology (2019) (Web Link)
 Ahmad, F., Rashid, H., Bhatia, K., Rehman, H., Kaur, M., Anjum, S., Ansari, R. A. and Raisuddin, S. (2012) “Modulatory Effect of a Unani Formulation (Jawarish amla sada) on Cyclophosphamide-induced Toxicity in Tumour Bearing Mice”, Journal of Advances in Medicine and Medical Research, 2(3), pp. 454-468. doi: 10.9734/BJMMR/2012/1228. (Web Link)